fentanyl - 1 a pharma s 75 µg/h matrixpflaster
1 a pharma gmbh (8013083) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 12,6 milligramm
dicloberl n 75
berlin-chemie aktiengesellschaft (4000014) - diclofenac-natrium - injektionslösung - teil 1 - injektionslösung; diclofenac-natrium (11900) 75 milligramm
fentadolon 75 µg/h matrixpflaster
mibe gmbh arzneimittel (8004658) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 14,4 milligramm
roferon-a 3 mio. i.e./0,5 ml fertigspritze mit injektionslösung
roche pharma ag (3001678) - interferon alfa-2a - injektionslösung - interferon alfa-2a (23546) 3 million i.e.
fentanyl abz 75 µg/h matrixpflaster
abz-pharma gmbh - geschäftsanschrift - (4238075) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 12,375 milligramm
fentanyl-ct 75 mikrogramm/h matrixpflaster
teva gmbh (3086597) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 12,375 milligramm
novothyral 75
merck healthcare germany gmbh (8128716) - levothyroxin-natrium; liothyronin-natrium - tablette - teil 1 - tablette; levothyroxin-natrium (07511) 75 mikrogramm; liothyronin-natrium (07513) 15 mikrogramm
isaris 75 filmtablette
roche pharma ag - doxepinhydrochlorid (ph.eur.) - filmtablette - doxepinhydrochlorid (ph.eur.) 84.795mg
aponal 75 filmtablette
roche pharma ag - doxepinhydrochlorid (ph.eur.) - filmtablette - doxepinhydrochlorid (ph.eur.) 84.795mg
mircera
roche registration gmbh - methoxy-polyethylenglycol-epoetin beta - anemia; kidney failure, chronic - antianämische präparate - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.